N-[4-[3,5-dimethyl-4-(5-methyl-1H-indazol-4-yl)pyrazol-1-yl]-3-fluorophenyl]prop-2-enamide
C22H20FN5O — CID 171357524
Data last refreshed: (MolForge compound catalog, from PubChem)
About N-[4-[3,5-dimethyl-4-(5-methyl-1H-indazol-4-yl)pyrazol-1-yl]-3-fluorophenyl]prop-2-enamide
N-[4-[3,5-dimethyl-4-(5-methyl-1H-indazol-4-yl)pyrazol-1-yl]-3-fluorophenyl]prop-2-enamide (PubChem CID 171357524) has the molecular formula C22H20FN5O and a molecular weight of 389.43 g/mol. Its IUPAC name is N-[4-[3,5-dimethyl-4-(5-methyl-1H-indazol-4-yl)pyrazol-1-yl]-3-fluorophenyl]prop-2-enamide.
Molecular Properties
| Compound Name | N-[4-[3,5-dimethyl-4-(5-methyl-1H-indazol-4-yl)pyrazol-1-yl]-3-fluorophenyl]prop-2-enamide |
|---|---|
| PubChem CID | 171357524 |
| Molecular Formula | C22H20FN5O |
| Molecular Weight | 389.43 g/mol |
| Exact Mass | 389.17 |
| IUPAC Name | N-[4-[3,5-dimethyl-4-(5-methyl-1H-indazol-4-yl)pyrazol-1-yl]-3-fluorophenyl]prop-2-enamide |
| SMILES | C=CC(=O)Nc1ccc(-n2nc(C)c(-c3c(C)ccc4[nH]ncc34)c2C)c(F)c1 |
| InChI | InChI=1S/C22H20FN5O/c1-5-20(29)25-15-7-9-19(17(23)10-15)28-14(4)22(13(3)27-28)21-12(2)6-8-18-16(21)11-24-26-18/h5-11H,1H2,2-4H3,(H,24,26)(H,25,29) |
| InChIKey | QICYTGBHUIUDSQ-UHFFFAOYSA-N |
| XLogP | 4.60 |
| TPSA | 75.60 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 4 |
| Rotatable Bonds | 4 |
| Heavy Atoms | 29 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 389.43 |
| LogP ≤ 5 | 4.60 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 4 |
Computed Properties (RDKit)
| Structural Alerts | {'alert_name': 'Michael_acceptor_1', 'substructure': 'N/A'} |
|---|
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 171357524 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.